UW Medicine MS Center Trials

UW Medicine MS Center	Welcome, Profile Billing Logout

UW Medicine MS Center

Welcome, Profile Billing Logout

0 Trials

8 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

McGee, Elisa

VISTA, NCT06083753: Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis

Active, not recruiting

168

PIPE-307 Dose A, PIPE-307 Dose B, Placebo

Contineum Therapeutics

Relapsing Remitting Multiple Sclerosis

08/25

09/25

TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting

N/A

900

Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso

Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society

Multiple Sclerosis, Relapsing-Remitting

08/26

PENS, NCT05081128: Efficacy in iNPH Shunting () Trial

Active, not recruiting

N/A

100

Europe, Canada, US

programmable CSF shunt valve, FDA-approved Certas Plus with Siphonguard

Johns Hopkins University, National Institute of Neurological Disorders and Stroke (NINDS)

Idiopathic Normal Pressure Hydrocephalus (INPH)

05/26

08/27

Dihenia, Bhupesh

SOSTOS, NCT05090371: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Recruiting

150

Canada, US

Ofatumumab, Disease modifying treatment (DMT)

Novartis Pharmaceuticals

Relapsing-Remitting Multiple Sclerosis

12/26

TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed

507

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

AbbVie

Parkinson Disease

01/24

02/24

TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed

522

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

Cerevel Therapeutics, LLC

Parkinson Disease

06/24

ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis

Active, not recruiting

1882

Europe, Canada, Japan, US, RoW

Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen

Novartis Pharmaceuticals

Relapsing Multiple Sclerosis

12/27

09/28

VISTA, NCT06083753: Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis

Active, not recruiting

168

PIPE-307 Dose A, PIPE-307 Dose B, Placebo

Contineum Therapeutics

Relapsing Remitting Multiple Sclerosis

08/25

09/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

McGee, Elisa

VISTA, NCT06083753: Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis

Active, not recruiting

168

PIPE-307 Dose A, PIPE-307 Dose B, Placebo

Contineum Therapeutics

Relapsing Remitting Multiple Sclerosis

08/25

09/25

TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting

N/A

900

Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society

Multiple Sclerosis, Relapsing-Remitting

08/26

PENS, NCT05081128: Efficacy in iNPH Shunting () Trial

Active, not recruiting

N/A

100

Europe, Canada, US

programmable CSF shunt valve, FDA-approved Certas Plus with Siphonguard

Johns Hopkins University, National Institute of Neurological Disorders and Stroke (NINDS)

Idiopathic Normal Pressure Hydrocephalus (INPH)

05/26

08/27

Dihenia, Bhupesh

SOSTOS, NCT05090371: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Recruiting

150

Canada, US

Ofatumumab, Disease modifying treatment (DMT)

Novartis Pharmaceuticals

Relapsing-Remitting Multiple Sclerosis

12/26

TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed

507

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

AbbVie

Parkinson Disease

01/24

02/24

TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed

522

Europe, Canada, US, RoW

Tavapadon, PF-06649751, CVL-751, Placebo

Cerevel Therapeutics, LLC

Parkinson Disease

06/24

ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis

Active, not recruiting

1882

Europe, Canada, Japan, US, RoW

Novartis Pharmaceuticals

Relapsing Multiple Sclerosis

12/27

09/28

VISTA, NCT06083753: Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis

Active, not recruiting

168

PIPE-307 Dose A, PIPE-307 Dose B, Placebo

Contineum Therapeutics

Relapsing Remitting Multiple Sclerosis

08/25

09/25

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites